AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Dementia: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)NCT05665088 · results posted 2026-10-01 · BioXcel Therapeutics Inc · 13 people · tests BXCL501, Matching Placebo A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)NCT04374136 · results posted 2026-09-21 · Alector Inc. · 119 people · tests Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 … Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's DiseaseNCT05267535 · results posted 2026-09-09 · Neurim Pharmaceuticals Ltd. · 216 people · tests Piromelatine 20 mg, Placebo A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409 · results posted 2026-08-13 · Axsome Therapeutics, Inc. · 408 people · tests AXS-05, Placebo An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509 · results posted 2026-06-25 · Axsome Therapeutics, Inc. · 139 people · tests AXS-05 (dextromethorphan-bupropion) Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)NCT03317067 · results posted 2026-05-13 · University Hospital, Clermont-Ferrand · 168 people · tests Dexmedetomidine, Placebo A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseNCT05891496 · results posted 2026-02-24 · Novo Nordisk A/S · 23 people · tests Semaglutide, Placebo Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)NCT05271552 · results posted 2025-12-31 · BioXcel Therapeutics Inc · 151 people · tests BXCL501, Matching Placebo A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseNCT05655520 · results posted 2025-12-17 · Supernus Pharmaceuticals, Inc. · 153 people · tests SAGE-718 A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)NCT05738486 · results posted 2025-11-14 · Eli Lilly and Company · 1175 people · tests Donanemab, Placebo, Dexamethasone An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsNCT04770220 · results posted 2025-11-10 · Alzheon Inc. · 325 people · tests Experimental: ALZ-801, Placebo Comparator: Placebo

Want these every week? Follow dementia and get a note on your phone with the new trials and papers.

🔔 Follow dementia
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy